TP53 and neoplasm: In high-grade serous ovarian carcinomas, we and others have shown that among TP53 mutation-positive tumor samples, between 60 and 70% harbor TP53 missense mutations, and the remaining 30–40% harbor p53-null mutations (Ahmed et al., 2010; Cancer Genome Atlas Research, 2011; Wojnarowicz et al., 2012).